Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Department of Hematology and Oncology, Mayo Clinic , Scottsdale, AZ , USA.
James M
JM
Bogenberger
Devora
D
Delman
Nanna
N
Hansen
Riccardo
R
Valdez
Veena
V
Fauble
Ruben A
RA
Mesa
Raoul
R
Tibes
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001374:Azacitidine / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism; D009596:Nitrophenols / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology*
C501332:ABT-737; D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D009596:Nitrophenols; D010879:Piperazines; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; D001374:Azacitidine; C579720:venetoclax